Status:
COMPLETED
Cognitive Function in Older Women With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy
Lead Sponsor:
City of Hope Medical Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Eligibility:
FEMALE
65+ years
Brief Summary
RATIONALE: Gathering information about cognitive function over time in postmenopausal women with breast cancer may help doctors learn about the long-term effects of aromatase inhibitor therapy and pla...
Detailed Description
OBJECTIVES: * Explore the impact of treatment with an aromatase inhibitor on the cognitive function of postmenopausal women with stage I-III breast cancer vs in cancer-free, age-matched healthy volun...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Meets 1 of the following criteria:
- Patient diagnosed with breast cancer
- Stage I-III disease
- Estrogen receptor- and/or progesterone receptor-positive
- Planning to start treatment with anastrozole or letrozole
- Age-matched healthy volunteer (control)
- No history of breast cancer
- Not receiving adjuvant aromatase inhibitor therapy
- PATIENT CHARACTERISTICS:
- Postmenopausal
- Able to converse, write, and read English
- No claustrophobia (patients participating in the PET scan correlative study)
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior hormonal therapy, including estrogen replacement therapy
- No previous treatment with CNS radiation
Exclusion
Key Trial Info
Start Date :
October 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00681928
Start Date
October 1 2007
End Date
January 1 2011
Last Update
December 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope Comprehensive Cancer Center
Duarte, California, United States, 91010-3000